ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

12 Dec 2021 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

11 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors

09 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting

04 Nov 2021 09:00:02 By Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

02 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

21 Oct 2021 07:00:02 By Nasdaq GlobeNewswire

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

07 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

01 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

16 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

07 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

12 Aug 2021 16:05:03 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

28 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

03 Jul 2021 07:15:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

14 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer

10 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

18 May 2021 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

17 May 2021 16:05:01 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

10 May 2021 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

21 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

05 Apr 2021 07:00:00 By Nasdaq GlobeNewswire